Literature DB >> 33327381

Effects of the Glass-Forming Ability and Annealing Conditions on Cocrystallization Behaviors via Rapid Solvent Removal: A Case Study of Voriconazole.

Si Nga Wong1, Susan Wing Sze Chan1, Xuexin Peng2, Bianfei Xuan1, Hok Wai Lee1, Henry H Y Tong3, Shing Fung Chow1.   

Abstract

The kinetic entrapment of molecules in an amorphous phase is a common obstacle to cocrystal screening using rapid solvent removal, especially for drugs with a moderate or high glass-forming ability (GFA). The aim of this study was to elucidate the effects of the coformer's GFA and annealing conditions on the nature of amorphous phase transformation to the cocrystal counterpart. Attempts were made to cocrystallize voriconazole (VRC) with four structural analogues, namely fumaric acid (FUM), tartaric acid (TAR), malic acid (MAL), and maleic acid (MAE). The overall GFA of VRC binary systems increased with decreasing glass transition temperatures (Tgs) of these diacids, which appeared as a critical parameter for predicting the cocrystallization propensity such that a high-Tg coformer is more desirable. A new 1:1 VRC-TAR cocrystal was successfully produced via a supercooled-mediated re-cocrystallization process, and characterized by PXRD, DSC, and FTIR. The cocrystal purity against the annealing temperature displayed a bell-shaped curve, with a threshold at 40 °C. The isothermal phase purity improved with annealing and adhered to the Kolmogorov-Johnson-Mehl-Avrami kinetics. The superior dissolution behavior of the VRC-TAR cocrystal could minimize VRC precipitation upon gastric emptying. This study offers a simple but useful guide for efficient cocrystal screening based on the Tg of structurally similar coformers, annealing temperature, and time.

Entities:  

Keywords:  amorphous; annealing temperature; cocrystal; glass-forming ability; rotary evaporation; voriconazole

Year:  2020        PMID: 33327381     DOI: 10.3390/pharmaceutics12121209

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  2 in total

1.  Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.

Authors:  Si Nga Wong; Jingwen Weng; Ignatius Ip; Ruipeng Chen; Richard Lakerveld; Richard Telford; Nicholas Blagden; Ian J Scowen; Shing Fung Chow
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

Review 2.  Improving the Physicochemical and Biopharmaceutical Properties of Active Pharmaceutical Ingredients Derived from Traditional Chinese Medicine through Cocrystal Engineering.

Authors:  Danyingzi Guan; Bianfei Xuan; Chengguang Wang; Ruitao Long; Yaqin Jiang; Lina Mao; Jinbing Kang; Ziwen Wang; Shing Fung Chow; Qun Zhou
Journal:  Pharmaceutics       Date:  2021-12-15       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.